Hematologic Malignancy
Core Binding Factor Acute Myeloid Leukemia
CI-CAN-00008828Explore in graph →
Hematologic6 active trials8 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008828Explore in graph →
Variants & evidence
11 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MYH11 Fusion4 | ||||||||
| (prognostic) | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11ALIAS | Prognostic | B | Supports Better Outcome | 5 | submitted | EID11788This study evaluated the independent prognostic significance of pretreatment cytogenetics based on the large Medical Research Council (MRC) AML 10 trial which enrolled a total of 1,966 patients (364 c… (full text at CIViC) PMID 9746770 · Grimwade et al., 1998 · Open in CIViC | civic |
| (diagnostic) | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11ALIAS | Diagnostic | B | Supports Positive | 5 | accepted | EID11791This is a Cancer and Leukemia Group B study on core binding factor (CBF) AML (2005): AML with RUNX1::RUNX1T1 (303 adult patients who received treatment) vs AML with CBFB::MYH11 (164 patients who recei… (full text at CIViC) PMID 16110030 · Marcucci et al., 2005 · Open in CIViC | civic |
| 〃 | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11ALIAS | Diagnostic | B | Supports Positive | 5 | accepted | EID11792A metanalysis study from the German AML Intergroup (2004) on AML-CBF included 8 German multicenter treatment trials enrolling patients with AML with RUNX1::RUNX1T1 (191 adult patients) and CBFB::MYH11… (full text at CIViC) PMID 15289486 · Schlenk et al., 2004 · Open in CIViC | civic |
| 〃 | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11ALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID11793A small study on 18 patients of AML with inv(16)(p13q22) [now known to correspond to CBFB::MYH11 fusion] identified abnormal eosinophils as a unique morphologic characteristic of this entity. 76.5% ac… (full text at CIViC) PMID 6577285 · Le Beau et al., 1983 · Open in CIViC | civic |
| FLT3 N676K1 | ||||||||
| Midostaurin + QuizartinibSequential | Core Binding Factor Acute Myeloid Leukemia | Predictive | B | Supports N/A | 3 | submitted | EID8263In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in 5 and 1 patients, respectively (… (full text at CIViC) PMID 23878140 · Opatz et al., 2013 · Open in CIViC | civic |
| KIT Mutation1 | ||||||||
| Dasatinib | Core Binding Factor Acute Myeloid Leukemia | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID8576This is a prospective clinical trial testing the safety and efficacy of adding dasatinib to chemotherapy (cytarabine-daunorubicin/HiDAC) in patients with Core Binding Factor (CBF) AML (i.e RUNX1-RUNX1… (full text at CIViC) PMID 32092139 · Marcucci et al., 2020 · Open in CIViC | civic |
| RUNX1T1 Fusion5 | ||||||||
| (prognostic) | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1ALIAS | Prognostic | A | Supports Better Outcome | 5 | accepted | EID11881This study evaluated the independent prognostic significance of pretreatment cytogenetics based on the large Medical Research Council (MRC) AML 10 trial which enrolled a total of 1,966 patients (364 c… (full text at CIViC) PMID 9746770 · Grimwade et al., 1998 · Open in CIViC | civic |
| (diagnostic) | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1ALIAS | Diagnostic | A | Supports Positive | 4 | accepted | EID11880This study evaluated the independent prognostic significance of pretreatment cytogenetics based on the large Medical Research Council (MRC) AML 10 trial which enrolled a total of 1,966 patients (364 c… (full text at CIViC) PMID 9746770 · Grimwade et al., 1998 · Open in CIViC | civic |
| 〃 | ||||||||
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Diagnostic |
| B |
| Supports Positive |
| 3 |
| accepted |
EID11878In this 1992 study, the authors isolated a clone containing the junction region of the (8;21)(q22;q22) translocation characteristic for acute myeloid leukemia with t(8;21). Using probes from the junct… (full text at CIViC) PMID 1391946 · Erickson et al., 1992 · Open in CIViC |
| civic |
| 〃 | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1ALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID11879The researchers analyzed immunophenotype in 30 cases of newly diagnosed pediatric acute myeloid leukemia (AML) exhibiting M2 morphology per French-American-British classification. They correlated thes… (full text at CIViC) PMID 1467524 · Hurwitz et al., 1992 · Open in CIViC | civic |
| 〃 | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1ALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID11882The authors of this 1997 paper compared morphologic and cytochemical features between 30 acute myeloid leukemia subtype M2 (AML-M2) patients with t(8;21) and 50 AML-M2 patients without t(8;21). Morp… (full text at CIViC) PMID 9180287 · Nakamura et al., 1997 · Open in CIViC | civic |